Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
Launched by BAYER · Oct 22, 2008
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 50 years (inclusive) at visit 1, for smokers up to 35 years (inclusive)
- • Otherwise healthy female subjects requesting contraception and currently using a levonorgestrel, gestodene or desogestrel containing oral contraceptive in a 21-day regimen and suffering from at least moderate pelvic pain, headache or both defined by an average value of \>/= 35 mm for the 3 highest values on a visual analogue scale during cycle days 22-28.
- • Normal or clinically insignificant cervical smear not requiring further follow up (or a normal result obtained within the last 6 months before screening)
- • Able to tolerate ibuprofen and willing to use only ibuprofen supplied for the study.
- Exclusion Criteria:
- • Women with any contraindication for oral contraceptive use
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Bern, , Switzerland
Zürich, , Switzerland
Frankfurt, , Germany
Essen, , Germany
Leipzig, Sachsen, Germany
Glasgow, , United Kingdom
Bangkok, , Thailand
Northwood, Middlesex, United Kingdom
Nedlands, Western Australia, Australia
Wuppertal, , Germany
Hamburg, , Germany
Nantes, , France
Dresden, Sachsen, Germany
Helsinki, , Finland
Basel, Basel Stadt, Switzerland
Saint Germain En Laye, , France
Kuopio, , Finland
Paris, , France
Toulouse, , France
Blacktown, New South Wales, Australia
Magdeburg, Sachsen Anhalt, Germany
Lübeck, Schleswig Holstein, Germany
Frankfurt, Hessen, Germany
Hannover, Niedersachsen, Germany
Brignoles, , France
México, D.F., , Mexico
Sydney, New South Wales, Australia
Wuppertal, Nordrhein Westfalen, Germany
Benidorm, Alicante, Spain
Petrer, Alicante, Spain
Glasgow, Stratchclyde, United Kingdom
Hermosillo, Sonora, Mexico
Hamburg, , Germany
London, , United Kingdom
Ashfield, New South Wales, Australia
Caringbah, New South Wales, Australia
Fortitude Valley, Queensland, Australia
Kipparing, Queensland, Australia
Adelaide, South Australia, Australia
Norwood, South Australia, Australia
Clayton, Victoria, Australia
Subiaco, Western Australia, Australia
Maison Lafitte, , France
Nancy, , France
Olivet, , France
Seclin, , France
Tarare, , France
Rheinstetten, Baden Württemberg, Germany
Bochum, Nordrhein Westfalen, Germany
Essen, Nordrhein Westfalen, Germany
Mexico, México, Mexico
Mexico, D.F., , Mexico
Gijón, Asturias, Spain
Barcelona, Catalunya, Spain
Madrid, , Spain
Cheadle, Cheshire, United Kingdom
Weston Super Mare, North Somerset, United Kingdom
Nottingham, Nottinghamshire, United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials